FG-2216

FG-2216 (IOX3) is a potent and orally active inhibitor of HIF prolyl hydroxylase-2 (PHD2), with an IC50 of 3.9 μM. FG-2216 induces robust erythropoietin and modest fetal hemoglobin in vivo[1][2][3].

Product Specifications

CAS Number

[223387-75-5]

Product Name Alternative

IOX3; YM311

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/FG-2216.html

Purity

99.46

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)CNC(C1=C(O)C2=C(C(Cl)=N1)C=CC=C2)=O

Molecular Formula

C12H9ClN2O4

Molecular Weight

280.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Hong YR, et al. [ (4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl) -amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues. Bioorg Med Chem Lett. 2013 Nov 1;23 (21) :5953-7.|[2]Hsieh MM, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007 Sep 15;110 (6) :2140-7.|[3]Bernhardt WM, et, al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010 Dec;21 (12) :2151-6.